Intraocular Pressure

The first quarter of 2024 has come to a close, but Healio’s ophthalmology meeting news coverage is just getting started.

Timolol maleate 0.5% microdrops delivered with the Nanodropper Adaptor met three noninferiority endpoints in lowering IOP compared with conventional timolol drops, according to a study.

The “365 breathing” technique significantly increased parasympathetic activity and reduced IOP and serum cortisol levels after 6 weeks in patients with glaucoma, according to a study published in the Journal of Glaucoma.

In the dynamic landscape of diabetic macular edema management, the PALADIN study continues to offer helpful insights into the outcomes of IOP-lowering surgery after treatment with Iluvien.

FRANKFURT, Germany — In this Healio Video Perspective from the ESCRS winter meeting, Kevin L. Waltz, OD, MD, speaks about the ViaLase femtosecond laser technology for high-precision trabeculotomy.

FRANKFURT, Germany — In this Healio Video Perspective from the ESCRS winter meeting, Emmanouil Xylouris, MD, discusses a poster exploring the clinical safety and efficacy of the fixOflex endocapsular implant.

Patients with advanced glaucoma should be offered trabeculectomy as their primary intervention, according to a study presented at the American Glaucoma Society meeting.

The travoprost intraocular implant demonstrated a reduction in IOP in patients with open-angle glaucoma or ocular hypertension 3 months after a single administration, according to a study published in Ophthalmology.

Modern glaucoma care is all about the patient, according to a speaker at the American Glaucoma Society meeting.

Skye Bioscience has completed enrollment for its phase 2a trial of SBI-100, a cannabinoid receptor type 1 agonist being developed for patients with primary open-angle glaucoma or ocular hypertension, according to a company press release.